Nuhey News

We talk about the MARKET

The Global Human Rabies Immunoglobulin (IM) Market to show 6.2% CAGR from 2022-28

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.

Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient’s passive immunization.

In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)

Due to the COVID-19 pandemic, the global Human Rabies Immunoglobulin (IM) market size is estimated to be worth US$ 396 million in 2021 and is forecast to a readjusted size of US$ 606.3 million by 2028 with a CAGR of 6.2% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Human Rabies Immunoglobulin (IM) market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Human Rabies Immunoglobulin (IM) landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Global Human Rabies Immunoglobulin (IM) key players include CSL Behring, Grifols, Sanofi, etc. Global top three manufacturers hold a share about 60%.

North America is the largest market, with a share over 30%, followed by China and Europe, both have a share about 45 percent.

In terms of product, HRIG is the largest segment, with a share over 85%. And in terms of application, the largest application is Category III Exposure, followed by Category II Exposure.

This report focuses on Human Rabies Immunoglobulin (IM) volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Human Rabies Immunoglobulin (IM) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and India, etc.

Request for a free sample or purchase this report at: https://www.themarketreports.com/report/global-human-rabies-immunoglobulin-im-market-research-report

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

  • ERIG
  • HRIG

Segment by Application

  • Category II Exposure
  • Category III Exposure

By Company

  • CSL Behring
  • Grifols
  • Sanofi
  • Sichuan Yuanda Shuyang
  • CNBG
  • Kamada
  • CBPO
  • Shuanglin Bio
  • Weiguang Bio
  • Shanghai RAAS
  • Bharat Serum
  • VINS

Production by Region

  • North America
  • Europe
  • China

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

 

Contact Details:

Mr. Shirish Gupta

Sales Manager

The Market Reports | Industry and Market Reports at its Best

Call: +1-631-407-1315 / +91-750-729-1479

Email: sales@themarketreports.com